Immunohistochemistry for the Novel Markers Glypican 3, PAX8, and p40 (ΔNp63) in Squamous Cell and Urothelial Carcinoma

American Journal of Clinical Pathology

Volumn 140, Issue 6, 2013, Pages 872-880

  Gailey, Michael P ^a   Bellizzi Dr , Andrew M ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Np63; Carcinoma of unknown primary; Glypican 3; Immunohistochemistry; P40; P63; PAX8; Squamous cell carcinoma; TAp63; Urothelial carcinoma

Indexed keywords

GLYPICAN 3; PROTEIN P40; TRANSCRIPTION FACTOR PAX8;

ANUS CARCINOMA; ARTICLE; ESOPHAGUS CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNX CARCINOMA; LUNG CARCINOMA; PENIS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; TRANSITIONAL CELL CARCINOMA; UTERINE CERVIX CARCINOMA;

ΔNP63; CARCINOMA OF UNKNOWN PRIMARY; GLYPICAN 3; IMMUNOHISTOCHEMISTRY; P40; P63; PAX8; SQUAMOUS CELL CARCINOMA; TAP63; UROTHELIAL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; CARCINOMA, TRANSITIONAL CELL; FEMALE; GLYPICANS; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE PROTEINS; PAIRED BOX TRANSCRIPTION FACTORS; PROTEIN ISOFORMS; SENSITIVITY AND SPECIFICITY; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84888271435     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP4NSKW5TLGTDS     Document Type: Article

References (39)

1. O'Neill CJ, McCluggage WG. p16 expression in the female genital tract and its value in diagnosis [review]. Adv Anat Pathol. 2006;13:8-15.
2. Lewis JS Jr. p16 Immunohistochemistry as a standalone test for risk stratification in oropharyngeal squamous cell carcinoma [review]. Head Neck Pathol. 2012l;6(suppl 1):S75- S82.
3. Kim H, Xu GL, Borczuk AC, et al. The heparan sulfate proteoglycan GPC3 is a potential lung tumor suppressor. Am J Respir Cell Mol Biol. 2003;29:694-701.
4. Powell CA, Xu G, Filmus J, et al. Oligonucleotide microarray analysis of lung adenocarcinoma in smokers and nonsmokers identifies GPC3 as a potential lung tumor suppressor. Chest. 2002;121(suppl):6S-7S.
5. Aviel-Ronen S, Lau SK, Pintilie M, et al. Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma. Mod Pathol. 2008;21:817-825.
6. Lin Q, Xiong LW, Pan XF, et al. Expression of GPC3 protein and its significance in lung squamous cell carcinoma. Med Oncol. 2012;29:663-669.
7. Laury AR, Perets R, Piao H, et al. A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol. 2011;35:816-826.
8. Tacha D, Zhou D, Cheng L. Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study. Appl Immunohistochem Mol Morphol. 2011;19:293-299.
9. Ozcan A, Shen SS, Hamilton C, et al. PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study. Mod Pathol. 2011;24:751-764.
10. Bishop JA, Teruya-Feldstein J, Westra WH, et al. p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol. 2012;25:405-415.
11. Baumhoer D, Tornillo L, Stadlmann S, et al. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am J Clin Pathol. 2008;129:899-906.
12. Li Y, Yang P. GPC5 gene and its related pathways in lung cancer. J Thorac Oncol. 2011;6:2-5.
13. Capurro MI, Xiang YY, Lobe C, et al. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res. 2005;65:6245-6254.
14. Kandil DH, Cooper K. Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more. Adv Anat Pathol. 2009;16:125-129.
15. Yamauchi N, Watanabe A, Hishinuma M, et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol. 2005;18:1591-1598.
16. Ligato S, Mandich D, Cartun RW. Utility of glypican-3 in differentiating hepatocellular carcinoma from other primary and metastatic lesions in FNA of the liver: an immunocytochemical study. Mod Pathol. 2008;21:626-631.
17. Shafizadeh N, Kakar S. Diagnosis of well-differentiated hepatocellular lesions: role of immunohistochemistry and other ancillary techniques. Adv Anat Pathol. 2011;18:438- 445.
18. Man XB, Tang L, Zhang BH, et al. Upregulation of glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers. Liver Int. 2005;25:962-966.
19. Toretsky JA, Zitomersky NL, Eskenazi AE, et al. Glypican-3 expression in Wilms tumor and hepatoblastoma. J Pediatr Hematol Oncol. 2001;23:496-499.
20. Zynger DL, Gupta A, Luan C, et al. Expression of glypican 3 in hepatoblastoma: an immunohistochemical study of 65 cases. Hum Pathol. 2008;39:224-230.
21. Saikali Z, Sinnett D. Expression of glypican 3 (GPC3) in embryonal tumors. Int J Cancer. 2000;89:418-422.
22. Zynger DL, Everton MJ, Dimov ND, et al. Expression of glypican 3 in ovarian and extragonadal germ cell tumors. Am J Clin Pathol. 2008;130:224-230.
23. Sugimura J, Foster RS, Cummings OW, et al. Gene expression profiling of early- and late-relapse nonseminomatous germ cell tumor and primitive neuroectodermal tumor of the testis. Clin Cancer Res. 2004;10:2368-2378.
24. Zynger DL, Dimov ND, Luan C, et al. Glypican 3: a novel marker in testicular germ cell tumors. Am J Surg Pathol. 2006;30:1570-1575.
25. Nakatsura T, Kageshita T, Ito S, et al. Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res. 2004;10:6612-6621.
26. Tsuta K, Tanabe Y, Yoshida A, et al. Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the Lung. J Thorac Oncol. 2011;6:1190- 1199.
27. Chi N, Epstein JA. Getting your Pax straight: Pax proteins in development and disease [review]. Trends Genet. 2002;18:41- 47.
28. Pellizzari L, Puppin C, Mariuzzi L, et al. PAX8 expression in human bladder cancer. Oncol Rep. 2006;16:1015-1020.
29. Tong GX, Yu WM, Beaubier NT, et al. Expression of PAX8 in normal and neoplastic renal tissues: an immunohistochemical study. Mod Pathol. 2009;22:1218- 1227.
30. Yang A, Kaghad M, Wang Y, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell. 1998;2:305-316.
31. Wu G, Nomoto S, Hoque MO, et al. DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development. Cancer Res. 2003;63:2351-2357.
32. Hedvat CV, Teruya-Feldstein J, Puig P, et al. Expression of p63 in diffuse large B-cell lymphoma. Appl Immunohistochem Mol Morphol. 2005;13:237-242.
33. Park CK, Oh YH. Expression of p63 in reactive hyperplasias and malignant lymphomas. J Korean Med Sci. 2005;20:752- 758.
34. Rush WL, Andriko JA, Taubenberger JK, et al. Primary anaplastic large cell lymphoma of the lung: a clinicopathologic study of five patients. Mod Pathol. 2000;13:1285-1292.
35. Gualco G, Weiss LM, Bacchi CE. Expression of p63 in anaplastic large cell lymphoma but not in classical Hodgkin's lymphoma. Hum Pathol. 2008;39:1505-1510.
36. Fukushima N, Satoh T, Sueoka N, et al. Clinico-pathological characteristics of p63 expression in B-cell lymphoma. Cancer Sci. 2006;97:1050-1055.
37. Hallack Neto AE, Siqueira SA, Dulley FL, et al. p63 protein expression in high risk diffuse large B-cell lymphoma. J Clin Pathol. 2009;62:77-79.
38. Crum CP, McKeon FD. p63 in epithelial survival, germ cell surveillance, and neoplasia. Annu Rev Pathol. 2010;5:349- 371.
39. Hibi K, Trink B, Patturajan M, et al. AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci U S A. 2000;97:5462-5467.